Condition: Neuroblastoma · Sponsor: Giselle Sholler
A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma.
This description comes directly from the study's public registry record.
BCC Enroll · 7175310003 · BCCEnroll@pennstatehealth.psu.edu
Always discuss trial participation with your own doctor first.
| University of Alabama/Children's of Alabama | Birmingham, Alabama, United States | Recruiting |
| Arkansas Children's Hospital | Little Rock, Arkansas, United States | Recruiting |
| UCSF Benioff Children's Hospital Oakland | Oakland, California, United States | Recruiting |
| Rady Children's Hospital | San Diego, California, United States | Recruiting |
| Connecticut Children's Hospital | Hartford, Connecticut, United States | Recruiting |
| Nicklaus Children's Miami | Miami, Florida, United States | Recruiting |
| Arnold Palmer Hospital for Children | Orlando, Florida, United States | Recruiting |
| St. Joseph's Children's Hospital | Tampa, Florida, United States | Recruiting |
| Augusta University Health | Augusta, Georgia, United States | Recruiting |
| Kapiolani Medical Center for Women and Children | Honolulu, Hawaii, United States | Recruiting |
| St. Lukes | Boise, Idaho, United States | Completed |
| Advocate Aurora Research Institute | Chicago, Illinois, United States | Completed |
+ 16 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02559778